Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 24, 2022

Pemigatinib for Pan-Cancer Patients With FGF/FGFR-Positive Advanced Malignancies

Annals of Oncology


Additional Info

Annals of Oncology
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
Ann. Oncol 2022 Feb 14;na(na)na, V Subbiah, NO Iannotti, M Gutierrez, DC Smith, L Féliz, CF Lihou, C Tian, IM Silverman, T Ji, M Saleh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading